What to Expect from Topical Calcineurin Inhibitors for Ashy Dermatosis

Ashy dermatosis, also called erythema dyschromicum perstans, causes grey or brown patches that can spread or change over time. A topical calcineurin inhibitor modifies local immune signalling rather than removing pigment directly. The aim is to reduce active inflammation and help prevent new change; existing colour may fade slowly and may not track with symptoms.

The medicine is generally used on selected affected areas according to an individual plan. Because several pigment conditions can look alike, a clinician may reassess the diagnosis if the pattern changes or treatment does not help.

Apply a small amount to clean, dry affected skin exactly as prescribed. A brief warm, stinging, or burning feeling can occur when treatment begins and often settles, but significant discomfort should be reported. Avoid covering the area tightly unless instructed, and keep the medicine away from eyes and inside the mouth.

Use gentle cleansers and moisturiser, avoid picking or harsh scrubbing, and protect exposed skin from ultraviolet light. Keep follow-up appointments so new patches, irritation, and the response of existing pigmentation can be assessed together.

Seek advice for marked swelling, blistering, severe burning, infection-like crusting, or a rapidly changing rash. Arrange a review if patches spread quickly, become painful, develop a different texture, or fail to settle with the agreed plan. New symptoms elsewhere should also be mentioned rather than treated without assessment.

Ask which areas to treat, how often to apply the medicine, what early irritation is acceptable, and how progress will be judged. Ask whether a skin examination or sampling is needed before changing treatment, and how to protect exposed patches from sunlight.